<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02376010</url>
  </required_header>
  <id_info>
    <org_study_id>21429</org_study_id>
    <nct_id>NCT02376010</nct_id>
  </id_info>
  <brief_title>Rivaroxaban Versus Warfarin in the Evaluation of Progression of Coronary Calcium</brief_title>
  <official_title>Rivaroxaban Versus Warfarin in the Evaluation of Progression of Coronary Calcium</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Current oral anti-coagulation for atrial fibrillation is most commonly performed with&#xD;
      warfarin. Warfarin is a vitamin K antagonist that has been shown in non-randomized trials to&#xD;
      increase vascular calcification. Increased vascular calcification has been tied to increased&#xD;
      cardiovascular events (CVE). This study will randomize patients currently taking warfarin to&#xD;
      either continue on warfarin or be switched to rivaroxaban. Rivaroxaban is an oral&#xD;
      anti-coagulant that works by inhibiting Factor Xa, and has no interaction with vitamin K.&#xD;
      This study is a randomized, open label study that will randomize 120 patients and have them&#xD;
      undergo blood tests and a calcium scan at baseline, and again after 12 months. Patients will&#xD;
      be seen quarterly for examinations, safety checks and supply of rivaroxaban, as well as&#xD;
      follow up INR testing for warfarin.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Rivaroxaban is a novel oral direct factor Xa inhibitor that has been shown to reduce the risk&#xD;
      of stroke in a similar population in comparison with warfarin. The rate of myocardial&#xD;
      infarction was 9% lower in the rivaroxaban group than in the warfarin group in the Rocket AF&#xD;
      study and similarly the myocardial infarction rate was 12% lower in the apixaban group in&#xD;
      Aristotle, but the difference was not significant in either trial. The potential of long term&#xD;
      benefit by avoiding VKA therapy may be much greater for a CV event reduction. The study&#xD;
      proposed will evaluate markers of CAC progression and atherosclerosis development, which have&#xD;
      long term outcome data supporting that slowing these processes will be associated with lower&#xD;
      CV events.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 2, 2015</start_date>
  <completion_date type="Actual">April 1, 2018</completion_date>
  <primary_completion_date type="Actual">April 1, 2018</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>randomized controlled trial, with blinded randomization to one of two groups.</intervention_model_description>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Coronary Artery Calcium (Serial Calcium Scans)</measure>
    <time_frame>1 year</time_frame>
    <description>serial calcium scans</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Atherosclerotic Plaque (Measures of Total Atherosclerosis Plaque on Serial CCTA)</measure>
    <time_frame>1 year</time_frame>
    <description>measures of total atherosclerosis plaque on serial CCTA</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">110</enrollment>
  <condition>Atherosclerosis</condition>
  <arm_group>
    <arm_group_label>rivaroxaban</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>rivaroxaban will be given to this cohort, once daily orally (15 or 20 mg, depending on GFR)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>warfarin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>warfarin orally once a day, titrated to INR of 2-3</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>rivaroxaban</intervention_name>
    <arm_group_label>rivaroxaban</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Warfarin</intervention_name>
    <arm_group_label>warfarin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:&#xD;
&#xD;
          1. Eligible patients with atrial fibrillation at enrollment or two or more episodes of&#xD;
             atrial fibrillation or flutter, as documented by electrocardiography, at least 2 weeks&#xD;
             apart in the 12 months before enrollment&#xD;
&#xD;
          2. Age 18-84&#xD;
&#xD;
          3. On Warfarin for 6 months prior to enrollment at a stable dose.&#xD;
&#xD;
          4. Willingness to participate in the study and ability to sign informed consent&#xD;
&#xD;
          5. Minimum CAC score of 10&#xD;
&#xD;
        Key Exclusion Criteria:&#xD;
&#xD;
          1. Atrial fibrillation due to a reversible cause, moderate or severe mitral stenosis, or&#xD;
             conditions other than atrial fibrillation that require anticoagulation (e.g., a&#xD;
             prosthetic heart valve)&#xD;
&#xD;
          2. Prior apixaban, dabigatran, rivaroxaban use.&#xD;
&#xD;
          3. A need for aspirin at a dose of &gt;165 mg a day or for both aspirin and clopidogrel,&#xD;
&#xD;
          4. Renal insufficiency (serum creatinine level of 12.5 mg per deciliter or calculated&#xD;
             creatinine clearance of &lt;50 ml per minute).&#xD;
&#xD;
          5. Serious bleeding event in the previous 6 months or a high risk of bleeding (eg, active&#xD;
             peptic ulcer disease, a platelet count of &lt;100,000/mm3 or hemoglobin level of &lt;10&#xD;
             g/dL, stroke within the previous 10 days, documented hemorrhagic tendencies, or blood&#xD;
             dyscrasias)&#xD;
&#xD;
          6. Weight in excess of 325 pounds&#xD;
&#xD;
          7. Resting hypotension (systolic blood pressure of &lt;90mmHg) or resting hypertension&#xD;
             (systolic blood pressure of &gt;170mmHg or diastolic blood pressure of &gt;110 mmHg).&#xD;
&#xD;
          8. History of active malignancy requiring concurrent chemotherapy.&#xD;
&#xD;
          9. Any unstable medical, psychiatric, or substance abuse disorder that in the opinion of&#xD;
             the principal investigator is likely to affect the subject's ability to complete the&#xD;
             study.&#xD;
&#xD;
         10. Known allergy to iodinated contrast material&#xD;
&#xD;
         11. Pregnancy or breast feeding&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>84 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Los Angeles Biomedical Research Institute</name>
      <address>
        <city>Torrance</city>
        <state>California</state>
        <zip>90502</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2017</verification_date>
  <study_first_submitted>February 24, 2015</study_first_submitted>
  <study_first_submitted_qc>March 2, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 3, 2015</study_first_posted>
  <results_first_submitted>April 1, 2021</results_first_submitted>
  <results_first_submitted_qc>July 21, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">July 22, 2021</results_first_posted>
  <last_update_submitted>July 21, 2021</last_update_submitted>
  <last_update_submitted_qc>July 21, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 22, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>atherosclerosis</keyword>
  <keyword>coronary artery disease</keyword>
  <keyword>cardiac CT</keyword>
  <keyword>computed tomographic angiography</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atherosclerosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Warfarin</mesh_term>
    <mesh_term>Rivaroxaban</mesh_term>
  </intervention_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>November 2, 2015</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/10/NCT02376010/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Rivaroxaban</title>
          <description>rivaroxaban will be given to this cohort, once daily orally (15 or 20 mg, depending on GFR)&#xD;
rivaroxaban</description>
        </group>
        <group group_id="P2">
          <title>Warfarin</title>
          <description>warfarin orally once a day, titrated to INR of 2-3&#xD;
Warfarin</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="55"/>
                <participants group_id="P2" count="55"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="46"/>
                <participants group_id="P2" count="51"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Rivaroxaban</title>
          <description>rivaroxaban will be given to this cohort, once daily orally (15 or 20 mg, depending on GFR)&#xD;
rivaroxaban</description>
        </group>
        <group group_id="B2">
          <title>Warfarin</title>
          <description>warfarin orally once a day, titrated to INR of 2-3&#xD;
Warfarin</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="55"/>
            <count group_id="B2" value="55"/>
            <count group_id="B3" value="110"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="42"/>
                    <measurement group_id="B2" value="41"/>
                    <measurement group_id="B3" value="83"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="62" spread="10"/>
                    <measurement group_id="B2" value="60" spread="11"/>
                    <measurement group_id="B3" value="61" spread="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                    <measurement group_id="B2" value="17"/>
                    <measurement group_id="B3" value="33"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="39"/>
                    <measurement group_id="B2" value="38"/>
                    <measurement group_id="B3" value="77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="22"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="43"/>
                    <measurement group_id="B2" value="42"/>
                    <measurement group_id="B3" value="85"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="55"/>
                    <measurement group_id="B2" value="55"/>
                    <measurement group_id="B3" value="110"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Coronary Artery Calcium (Serial Calcium Scans)</title>
        <description>serial calcium scans</description>
        <time_frame>1 year</time_frame>
        <population>patients completed second scan with interpretable data</population>
        <group_list>
          <group group_id="O1">
            <title>Rivaroxaban</title>
            <description>rivaroxaban will be given to this cohort, once daily orally (15 or 20 mg, depending on GFR)&#xD;
rivaroxaban</description>
          </group>
          <group group_id="O2">
            <title>Warfarin</title>
            <description>warfarin orally once a day, titrated to INR of 2-3&#xD;
Warfarin</description>
          </group>
        </group_list>
        <measure>
          <title>Coronary Artery Calcium (Serial Calcium Scans)</title>
          <description>serial calcium scans</description>
          <population>patients completed second scan with interpretable data</population>
          <units>mm cubed</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="46"/>
                <count group_id="O2" value="51"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26.3" lower_limit="4.5" upper_limit="61.5"/>
                    <measurement group_id="O2" value="40.5" lower_limit="9.6" upper_limit="97.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Atherosclerotic Plaque (Measures of Total Atherosclerosis Plaque on Serial CCTA)</title>
        <description>measures of total atherosclerosis plaque on serial CCTA</description>
        <time_frame>1 year</time_frame>
        <population>volume of plaque in patients completing study</population>
        <group_list>
          <group group_id="O1">
            <title>Rivaroxaban</title>
            <description>rivaroxaban will be given to this cohort, once daily orally (15 or 20 mg, depending on GFR)&#xD;
rivaroxaban</description>
          </group>
          <group group_id="O2">
            <title>Warfarin</title>
            <description>warfarin orally once a day, titrated to INR of 2-3&#xD;
Warfarin</description>
          </group>
        </group_list>
        <measure>
          <title>Atherosclerotic Plaque (Measures of Total Atherosclerosis Plaque on Serial CCTA)</title>
          <description>measures of total atherosclerosis plaque on serial CCTA</description>
          <population>volume of plaque in patients completing study</population>
          <units>mm cubed</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="46"/>
                <count group_id="O2" value="51"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.1" lower_limit="0" upper_limit="45"/>
                    <measurement group_id="O2" value="30.1" lower_limit="2" upper_limit="72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>1 year</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Rivaroxaban</title>
          <description>rivaroxaban will be given to this cohort, once daily orally (15 or 20 mg, depending on GFR)&#xD;
rivaroxaban</description>
        </group>
        <group group_id="E2">
          <title>Warfarin</title>
          <description>warfarin orally once a day, titrated to INR of 2-3&#xD;
Warfarin</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="51"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="46"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="51"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>minor bleeding</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="46"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="51"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Matthew Budoff</name_or_title>
      <organization>Lundquist Institute</organization>
      <phone>3102224107</phone>
      <email>mbudoff@lundquist.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

